| Previous Close | 2.94 |
| Open | 3.16 |
| Bid | 1.50 x 3000 |
| Ask | 3.44 x 800 |
| Day's Range | 2.90 - 3.19 |
| 52 Week Range | 2.51 - 4.40 |
| Volume | 15,583 |
| Avg. Volume | 33,413 |
| Market Cap | 19.013M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.41 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe without any challenges to its patent for AD04, which was granted by the European Patent Office (EPO) as EP 2801625 B1 and validated in 2018 in 36 European countries . William Stilley, CEO of Adial Pharmaceuticals, stated, “Following our recent patent award by the European Patent Office, we have now surpassed the opposition period for challenges, a key milestone in Europe, as it makes it much more difficult for potential competitors to challenge this patent in the future. The fact we were not only awarded the patent, but also faced no challenges, reinforces the strength of the patent.
ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced successful results related to the stability testing of the clinical trial material for its lead drug candidate, AD04, a genetically targeted therapeutic agent being developed to treat alcohol use disorder (AUD). The program indicated stability at the four-year time point for both the active drug candidate and the placebo tablets that had been previously manufactured for use in clinical trials.
ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and its lead drug for alcohol use disorder (AUD), will ring The Nasdaq Stock Market Opening Bell at the Nasdaq MarketSite in Times Square at 9:30 AM Eastern time today, Tuesday, September 4, 2018. The bell ringing ceremony will be held in honor of Adial Pharmaceuticals’ recent initial public offering (IPO) and listing on the Nasdaq Stock Market. “We are honored to ring the opening bell this morning in celebration of our IPO and listing on Nasdaq,” said William Stilley, Chief Executive Officer of Adial Pharmaceuticals.
ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today commented on the article published on Thursday, August 23rd, in The Lancet, which reports that alcohol is the number one cause of death globally among both men and women ages 15 to 49 years. The Lancet is one of the world’s leading medical journals with open access funded by the Bill & Melinda Gates Foundation. “This milestone Lancet article sheds bright light on the dangers of alcohol and the massive global mortality it inflicts.
ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the appointment of Monika Z. Rogozinska as Senior Vice President of Drug and Business Development. Prior to joining Adial, Ms. Rogozinska served as Vice President and Head of Portfolio, Program & Project Management at ECRC in Boston, where she managed a portfolio of complex projects as the clinical contact and spokesperson for potential licensing, acquisition, collaborations, co-development agreements and strategic alliances. Previously, Ms. Rogozinska served as Senior Director and Global Program Leader at EMD Serono, an affiliate of Merck KGaA, where she led the clinical development, regulatory submissions and lifecycle management of various drugs under clinical development including Bavencio® (avelumab).
Dawson James Securities, Inc. announced the closing on July 31st of the initial public offering for Adial Pharmaceuticals, Inc. (NASDAQ:ADIL and ADILW) for gross proceeds of $7.32 million, prior to deducting underwriting discounts and commissions and offering expenses. The offering was comprised of 1,464,000 units, priced at a public offering price of $5.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $6.25 per share. The shares of common stock and warrants comprising the units were transferable immediately upon issuance.
Adial Pharmaceuticals, Inc. (ADIL) (ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the closing of its initial public offering of units for gross proceeds of $7.32 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering was comprised of 1,464,000 units, priced at a public offering price of $5.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $6.25 per share. The shares of common stock and warrants comprising the units were transferable immediately upon issuance.
Adial Pharmaceuticals, Inc. (ADIL) (NASDAQ:ADILW), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder, today announced the pricing of its initial public offering of units for gross proceeds of $7.32 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is comprised of 1,464,000 units, priced at a public offering price of $5.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock at an exercise price of $6.25 per share. The common stock and warrants are expected to begin trading on The NASDAQ Capital Market on July 27, 2018 under the ticker symbols “ADIL,” and “ADILW,” respectively.